What is Robert W. Selander’s HEALTHEQUITY (HQY) share ownership after this Form 4 grant?

After the reported grant, Robert W. Selander directly owns 89,849 shares of HEALTHEQUITY common stock. This figure includes the impact of the 2,877-share restricted stock unit award reported, as shown in the total shares following the transaction field in the filing.

HealthEquity (HQY) director Selander receives 2,877-share restricted stock grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

SELANDER ROBERT W reported acquisition or exercise transactions in this Form 4 filing.

HEALTHEQUITY, INC. director Robert W. Selander received an equity award of 2,877 shares of common stock on June 25, 2026. The award is structured as restricted stock units, each representing the right to receive one share of common stock at vesting.

The restricted stock units vest in full on the earlier of June 25, 2027 or the company’s next annual stockholder meeting in June 2027, after which vested shares will be delivered to Selander. Following this grant, he directly owns 89,849 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SELANDER ROBERT W

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,877	$0.00	--

Holdings After Transaction: Common Stock — 89,849 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

RSU grant size: 2,877 restricted stock units Grant price: $0.00 per share Shares owned after grant: 89,849 shares +2 more

5 metrics

RSU grant size 2,877 restricted stock units Grant to director Robert W. Selander on June 25, 2026

Grant price $0.00 per share Compensation-related award, not open-market purchase

Shares owned after grant 89,849 shares Total common stock directly held following transaction

Vesting date June 25, 2027 Earlier of this date or next annual stockholder meeting

Security type Common Stock Underlying security for the restricted stock units

Key Terms

restricted stock unit, vest in full, annual stockholder meeting, contingent right

4 terms

restricted stock unit financial

"Each restricted stock unit represents a contingent right to receive one share"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

vest in full financial

"The restricted stock units vest in full on the earlier of; (i) June 25, 2027"

annual stockholder meeting financial

"or (ii) the date of the issuer's next annual stockholder meeting in June 2027"

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

contingent right financial

"represents a contingent right to receive one share of the issuer's common stock"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:18 PM Accepted by SEC EDGAR 06/29/2026 - 04:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SELANDER ROBERT W

(Last)

(First)

(Middle)

C/O HEALTHEQUITY, INC.

15 W. SCENIC POINTE DR., STE. 100

(Street)

DRAPER

UTAH

84020

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HEALTHEQUITY, INC. [ HQY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/25/2026		A		2,877⁽¹⁾	A	$0	89,849	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest in full on the earlier of; (i) June 25, 2027, or (ii) the date of the issuer's next annual stockholder meeting in June 2027. Vested shares will be delivered to the reporting person upon vesting.

Remarks:

The Power of Attorney given by Mr. Selander was previously filed with the U.S. Securities and Exchange Commission on June 26, 2023, as an exhibit to a statement on Form 4 filed by Mr. Selander with respect to HealthEquity, Inc. and is hereby incorporated by reference.

	/s/ /s/ Michael Newton , Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did HEALTHEQUITY (HQY) director Robert W. Selander report on this Form 4?

Director Robert W. Selander reported receiving an equity award of 2,877 restricted stock units of HEALTHEQUITY common stock. These units were granted as compensation and increase his direct holdings to 89,849 shares after the transaction, according to the Form 4 details.

How many HEALTHEQUITY (HQY) shares did Robert W. Selander acquire in this transaction?

Robert W. Selander acquired 2,877 restricted stock units tied to HEALTHEQUITY common stock. Each unit represents a contingent right to one share, delivered upon vesting. The grant price is shown as $0.00 per share, reflecting a compensation award rather than an open-market purchase.

When do Robert W. Selander’s HEALTHEQUITY (HQY) restricted stock units vest?

The 2,877 restricted stock units vest in full on the earlier of June 25, 2027 or the date of HEALTHEQUITY’s next annual stockholder meeting in June 2027. Once vested, the corresponding common shares will be delivered to Selander, as described in the footnote.

Is the HEALTHEQUITY (HQY) Form 4 transaction an open-market buy or a compensation grant?

The Form 4 describes a compensation-related grant, not an open-market buy. The transaction code is “A” for a grant or award, with a price of $0.00 per share, and the footnote clarifies these are restricted stock units that convert into shares upon vesting.

How are the HEALTHEQUITY (HQY) restricted stock units described in the Form 4 footnote?

Each restricted stock unit is described as a contingent right to receive one share of HEALTHEQUITY common stock. The units vest in full on the earlier of June 25, 2027 or the next annual stockholder meeting, and vested shares will be delivered to Robert W. Selander upon vesting.